Literature DB >> 22217876

AMG 837: a potent, orally bioavailable GPR40 agonist.

Jonathan B Houze1, Liusheng Zhu, Ying Sun, Michelle Akerman, Wei Qiu, Alex J Zhang, Rajiv Sharma, Michael Schmitt, Yingcai Wang, Jiwen Liu, Jinqian Liu, Julio C Medina, Jeff D Reagan, Jian Luo, George Tonn, Jane Zhang, Jenny Ying-Lin Lu, Michael Chen, Edwin Lopez, Kathy Nguyen, Li Yang, Liang Tang, Hui Tian, Steven J Shuttleworth, Daniel C-H Lin.   

Abstract

The discovery that certain long chain fatty acids potentiate glucose stimulated insulin secretion through the previously orphan receptor GPR40 sparked interest in GPR40 agonists as potential antidiabetic agents. Optimization of a series of β-substituted phenylpropanoic acids led to the identification of (S)-3-(4-((4'-(trifluoromethyl)biphenyl-3-yl)methoxy)phenyl)hex-4-ynoic acid (AMG 837) as a potent GPR40 agonist with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22217876     DOI: 10.1016/j.bmcl.2011.10.118

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.940


  32 in total

1.  Design and Synthesis of Novel, Selective GPR40 AgoPAMs.

Authors:  Christopher W Plummer; Matthew J Clements; Helen Chen; Murali Rajagopalan; Hubert Josien; William K Hagmann; Michael Miller; Maria E Trujillo; Melissa Kirkland; Daniel Kosinski; Joel Mane; Michele Pachanski; Boonlert Cheewatrakoolpong; Andrew F Nolting; Robert Orr; Melodie Christensen; Louis-Charles Campeau; Michael J Wright; Randal Bugianesi; Sarah Souza; Xiaoping Zhang; Jerry Di Salvo; Adam B Weinglass; Richard Tschirret-Guth; Ravi Nargund; Andrew D Howard; Steven L Colletti
Journal:  ACS Med Chem Lett       Date:  2017-01-23       Impact factor: 4.345

2.  Structure-Activity Relationship of Novel and Selective Biaryl-Chroman GPR40 AgoPAMs.

Authors:  Helen Y Chen; Christopher W Plummer; Dong Xiao; Harry R Chobanian; Duane DeMong; Michael Miller; Maria E Trujillo; Melissa Kirkland; Daniel Kosinski; Joel Mane; Michele Pachanski; Boonlert Cheewatrakoolpong; Jerry Di Salvo; Brande Thomas-Fowlkes; Sarah Souza; Daniel A Tatosian; Qing Chen; Michael J Hafey; Robert Houle; Andrew F Nolting; Robert Orr; Juliann Ehrhart; Adam B Weinglass; Richard Tschirret-Guth; Andrew D Howard; Steven L Colletti
Journal:  ACS Med Chem Lett       Date:  2018-06-14       Impact factor: 4.345

3.  Discovery of AM-6226: A Potent and Orally Bioavailable GPR40 Full Agonist That Displays Efficacy in Nonhuman Primates.

Authors:  Sean P Brown; Paul Dransfield; Marc Vimolratana; Liusheng Zhu; Jian Luo; Jane Zhang; XianYun Jiao; Vatee Pattaropong; Simon Wong; Run Zhuang; Gayathri Swaminath; Jonathan B Houze; Daniel C-H Lin
Journal:  ACS Med Chem Lett       Date:  2018-06-06       Impact factor: 4.345

4.  Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist.

Authors:  Rieko Takano; Masao Yoshida; Masahiro Inoue; Takeshi Honda; Ryutaro Nakashima; Koji Matsumoto; Tatsuya Yano; Tsuneaki Ogata; Nobuaki Watanabe; Masakazu Hirouchi; Tomoko Yoneyama; Shuichiro Ito; Narihiro Toda
Journal:  ACS Med Chem Lett       Date:  2015-01-13       Impact factor: 4.345

5.  Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.

Authors:  Sean P Brown; Paul J Dransfield; Marc Vimolratana; XianYun Jiao; Liusheng Zhu; Vatee Pattaropong; Ying Sun; Jinqian Liu; Jian Luo; Jane Zhang; Simon Wong; Run Zhuang; Qi Guo; Frank Li; Julio C Medina; Gayathri Swaminath; Daniel C-H Lin; Jonathan B Houze
Journal:  ACS Med Chem Lett       Date:  2012-08-15       Impact factor: 4.345

6.  SAR Studies of Indole-5-propanoic Acid Derivatives To Develop Novel GPR40 Agonists.

Authors:  Dong-Oh Yoon; Xiaodi Zhao; Dohyun Son; Jung Tae Han; Jaesook Yun; Dongyun Shin; Hyun-Ju Park
Journal:  ACS Med Chem Lett       Date:  2017-11-21       Impact factor: 4.345

7.  Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles.

Authors:  Yingcai Wang; Jiwen Jim Liu; Paul J Dransfield; Liusheng Zhu; Zhongyu Wang; Xiaohui Du; Xianyun Jiao; Yongli Su; An-Rong Li; Sean P Brown; Annie Kasparian; Marc Vimolratana; Ming Yu; Vatee Pattaropong; Jonathan B Houze; Gayathri Swaminath; Thanhvien Tran; Khanh Nguyen; Qi Guo; Jane Zhang; Run Zhuang; Frank Li; Lynn Miao; Michael D Bartberger; Tiffany L Correll; David Chow; Simon Wong; Jian Luo; Daniel C-H Lin; Julio C Medina
Journal:  ACS Med Chem Lett       Date:  2013-05-07       Impact factor: 4.345

8.  Optimization of GPR40 Agonists for Type 2 Diabetes.

Authors:  Jiwen Jim Liu; Yingcai Wang; Zhihua Ma; Mike Schmitt; Liusheng Zhu; Sean P Brown; Paul J Dransfield; Ying Sun; Rajiv Sharma; Qi Guo; Run Zhuang; Jane Zhang; Jian Luo; George R Tonn; Simon Wong; Gayathri Swaminath; Julio C Medina; Daniel C-H Lin; Jonathan B Houze
Journal:  ACS Med Chem Lett       Date:  2014-02-06       Impact factor: 4.345

9.  β-Arrestin Recruitment and Biased Agonism at Free Fatty Acid Receptor 1.

Authors:  Arturo D Mancini; Gyslaine Bertrand; Kevin Vivot; Éric Carpentier; Caroline Tremblay; Julien Ghislain; Michel Bouvier; Vincent Poitout
Journal:  J Biol Chem       Date:  2015-07-08       Impact factor: 5.157

10.  In vitro and mouse in vivo characterization of the potent free fatty acid 1 receptor agonist TUG-469.

Authors:  C Urban; A Hamacher; H J Partke; M Roden; S Schinner; E Christiansen; M E Due-Hansen; T Ulven; H Gohlke; M U Kassack
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-07-17       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.